Study Finds 20% of Cancer Drugs in 4 African Nations Defective
By
woldemariam
The bagel they save for the regulars. Don't skim, savour.
Summary
A research study reveals that nearly 20% of cancer drugs in four African nations are defective, lacking essential ingredients for treating the disease. The issue stems from challenges in regulating therapeutics across the continent.
Key quotes
· 3 pulledAn alarming number of people across Africa may be taking cancer drugs that don't contain the vital ingredients needed to contain or reduce their disease.
Across Africa, cancer medications have been found to be substandard or counterfeit.
They tested nearly 200 unique products across several brands.
You might also wanna read
Google's Debug program seeks EPA approval to release 64 million modified mosquitoes in California and Florida
Google's Debug program plans to release up to 64 million genetically modified "good" mosquitoes in California and Florida over two years to
bit.ly·1h ago
Researchers develop phage-based preventive treatment for newborn meningitis caused by E. coli K1
Researchers from the Biozentrum, University of Basel, and ETH Zurich have developed a novel preventive treatment for newborn meningitis caus
biozentrum.unibas.ch·2h ago
Daily pill daraxonrasib doubles survival for metastatic pancreatic cancer patients with KRAS mutation
A new daily pill called daraxonrasib has been shown to double survival time for metastatic pancreatic cancer patients with a KRAS mutation.
bbc.co.uk·5h ago
Exploring the science behind quantum effects in healthcare: separating research from pseudoscience
The article explores the intersection of quantum physics and healthcare, distinguishing between pseudoscientific "quantum therapies" and leg
newscientist.com·7h ago
Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
chicagotribune.com·7h agoExperimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
chicagotribune.com·7h ago